Assessing the heterogeneity of treatment effects by identifying the treatment benefit rate and treatment harm rate
From MaRDI portal
Recommendations
- Treatment benefit and treatment harm rate to characterize heterogeneity in treatment effect
- Assessing the treatment effect heterogeneity with a latent variable
- Using secondary outcome to sharpen bounds for treatment harm rate in characterizing heterogeneity
- Assessing treatment effect heterogeneity in clinical trials with blocked binary outcomes
- Estimating treatment effect heterogeneity for binary outcomes via Dirichlet multinomial constraints
Cited in
(5)- Treatment benefit and treatment harm rate to characterize heterogeneity in treatment effect
- A Generalized Estimator of the Attributable Benefit of an Optimal Treatment Regime
- Assessing the treatment effect heterogeneity with a latent variable
- Using secondary outcome to sharpen bounds for treatment harm rate in characterizing heterogeneity
- Assessing treatment effect heterogeneity in clinical trials with blocked binary outcomes
This page was built for publication: Assessing the heterogeneity of treatment effects by identifying the treatment benefit rate and treatment harm rate
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q4602119)